

1 **Predicting cohort-specific cervical cancer incidence from population-based HPV**
2 **prevalence surveys: a worldwide study**

3

4 Rosa Schulte-Frohlinde, BA^{1,2}, Damien Georges, MSc¹, Gary M. Clifford, PhD¹, Iacopo
5 Baussano, MD^{1*}

6

7 **Author affiliations:**

8 ¹International Agency for Research on Cancer, Lyon, France;

9 ²Department of Virology, University of Leipzig, Leipzig, Germany;

10

11 *Address for correspondence: Dr Iacopo Baussano, International Agency for Research on
12 Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France; Tel.: +33-472738048; Fax:
13 +33-472738345; email: baussanoi@iarc.fr

14

15 **Short title:** Cervical cancer risk among HPV positive women

16 **Keywords:** Cervical cancer; HPV infection; risk prediction.

17 **Main text word count:** 3066

18 **Abstract word count:** 266

19 **Number of references:** 30

20 **Tables:** 3; **Figures:** 3;

21 **Appendix: Supplementary figures:** 2; **Supplementary tables:** 6.

22

23

24 **Abbreviations:**

25 HIC, high-income countries; HR HPV, high-risk human papillomavirus; IARC, International
26 Agency for Research on Cancer; LMIC, low and middle-income countries; PI, prediction
27 interval.

28

29

58 **Abstract**

59 **Background** Predictions of cervical cancer burden and impact of control measures are often
60 modelled from HPV prevalence. However, predictions could be improved by data on time
61 between prevalent HPV detection and cervical cancer occurrence.

62 **Methods** Based upon high-risk (HR) HPV prevalence and cervical cancer incidence in the same
63 birth cohorts from 17 worldwide locations, and informed by individual-level data on age at HR
64 HPV detection and on sexual debut, we built a mixed model to predict cervical cancer incidence
65 up to 14 years following prevalent HR HPV detection.

66 **Findings** Cervical cancer incidence increased significantly during the 14 years following HR
67 HPV detection in women <35 years, e.g. from 0·02 (95% CI 0·003–0·06) per 1000 within 1 year
68 to 2·8 (1·2–6·5) at 14 years for unscreened women, but remained relatively constant following
69 prevalent HR HPV detection above 35 years, e.g. from 5·4 (2·5–11) per 1000 within 1 year to
70 6·4 (2·4–17·1) at 14 years for unscreened HR HPV positive women aged 45–54 years. Age at
71 sexual debut was a significant modifier of cervical cancer incidence in HR HPV positive women
72 aged <25, but less so at older ages, whereas screening was a modifier in women \geq 35 years.
73 Lastly, we predicted annual number and incidence of cervical cancer in ten additional IARC
74 HPV prevalence survey locations without representative cancer incidence data.

75 **Interpretation** These findings can inform cervical cancer control programmes, particularly in
76 settings without cancer registries, as they allow prediction of future cervical cancer burden from
77 population-based surveys of HPV prevalence.

78 **Funding** Bill & Melinda Gates Foundation; Canadian Institutes of Health Research.

79

80

81 **Introduction**

82 Despite being largely preventable, cervical cancer is a leading cause of morbidity and mortality
83 among women worldwide with approximately 570 000 new cases and 310 000 deaths in 2018.¹
84 Nearly half of the cases are diagnosed in women younger than 50 years of age and more than
85 two-thirds occur in low and middle-income countries (LMICs).²

86 Persistent infection with one of 13 high-risk (HR) human papillomavirus (HPV) types is
87 the necessary cause of cervical cancer.³ HPV16 and 18, targeted by all licensed vaccines, are
88 responsible for 70% of cervical cancer; whereas HPV types 31/33/45/52/58 targeted by the
89 nonavalent vaccine are responsible for another 18%.⁴ HPV vaccines have demonstrated high
90 safety^{5,6} and efficacy against persistent HPV infections, pre-cancerous lesions.⁷ Recent data also
91 suggest high efficacy against invasive cervical cancers.⁸ HPV vaccination programs have been
92 shown to be cost-effective in a wide range of settings and conditions.⁹ Nevertheless, HPV
93 vaccine has been introduced mostly in high-resource settings, whereas access to HPV
94 vaccination remains limited especially in LMICs, in particular Africa and Asia.¹⁰ Similarly, the
95 coverage of cervical cancer screening, which has been shown to be effective in controlling the
96 burden of cervical cancer in high-income countries (HICs), is highly heterogeneous worldwide
97 and remains very low in LMICs.¹¹ HPV vaccination, cervical cancer screening, and the
98 management of detected disease are the main components of the recent strategy launched by
99 WHO to eliminate cervical cancer as a public health problem.¹²

100 An accurate quantification of cervical cancer burden is essential to inform the planning of
101 cancer control programmes and to monitor the impact of control measures. The most valid
102 estimates of cancer burden are obtained from population-based cancer registries, which are,
103 however, resource demanding. On a global scale, about a third of countries (65 countries) have

104 high quality national (or subnational) data on cancer incidence,¹³ but this coverage, although
105 improving in LMICs, remains mostly confined to HICs. Hence, present and future trends of
106 cervical cancer incidence in most LMIC remain, and will remain, unknown.

107 Both mathematical¹⁴ and statistical¹⁵ models are extensively used to predict the burden of
108 cervical cancer and to project the impact of control measures in absence of local high quality
109 data. Nevertheless, the average time between HPV infection acquisition and cervical cancer
110 occurrence remains difficult to assess, firstly because it is far more feasible to have data on
111 prevalence rather than on incidence of HPV, and also because follow-up of pre-cancerous lesions
112 without treatment to understand their cervical cancer incidence is unethical.¹⁶ This uncertainty
113 may affect the validity of the cervical cancer risk estimates and of the expected impact of
114 preventive measures in specific populations.

115 To partially overcome this limitation, we have conducted a birth cohort-specific
116 ecological study accounting for time-lag between HR HPV prevalence measurement and cervical
117 cancer detection, hereafter labelled as “time-lag” for short, to describe the age-
118 specific association between HR HPV prevalence and cervical cancer incidence in the same birth
119 cohorts and to estimate cervical cancer incidence rates in HR HPV positive women.

120

121

122

123

124

125

126

127 **Methods**

128 **Data sources**

129 Age-stratified and population-based HR HPV prevalence data were obtained from the
130 International Agency for Research on Cancer (IARC) HPV Prevalence Surveys database
131 (appendix p 2, Fig S1). All cross-sectional surveys (n=28) used a standardized protocol for
132 population-based recruitment and detection of HPV in cervical cell samples using a GP5+/6+-
133 based PCR assay detecting at least 36 types.¹⁷ The following HPV types were defined as HR
134 types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. A woman was excluded from the
135 prevalence estimate if known to be currently pregnant or hysterectomised, if data on age or HPV
136 status was missing or if her cervical specimen was beta-globulin negative.

137 Cervical cancer incidence data were extracted from cancer registries included in Cancer
138 Incidence in Five Continents (CI5), Volume VIII-XI, a series of monographs published every
139 five years by IARC and the International Association of Cancer Registries (IACR) including
140 age-stratified data from high quality cancer registries worldwide.^{13,18-20}

141 **Association between HR HPV prevalence and cervical cancer incidence**

142 HR HPV prevalence and cervical cancer incidence data in the same birth cohorts were available
143 for 17 locations (appendix p 2, Fig S1 and appendix p 7, Table S1) and were used to describe the
144 age-specific effect of HR HPV prevalence on cervical cancer incidence. For 12 locations, HR
145 HPV prevalence survey data and incidence data from cancer registry were available from the
146 same geographic area. For the prevalence studies in Warsaw, Poland; Barcelona, Spain; Bogota,
147 Colombia; Shanxi, China; and Tehran, Iran, we selected cancer registries, with comparable
148 characteristics whenever possible, in the same region or country, namely: Kielce, showing
149 similarly low rates as Warsaw in previous years; Tarragona, the next largest city after Barcelona

150 in the region of Catalonia; Cali, the largest Colombian cancer registry; Cixian, as the study in
151 Shanxi also included women from this region; and Gholestan province in Iran.

152 We stratified our populations in 10-year age groups (25-34, 35-44, 45-54, and 55-64-
153 year-old at HPV detection) and assessed the association between age-specific HR HPV
154 prevalence and cervical cancer incidence for the same 10-year birth cohort fitting an additive
155 Poisson regression model (without an intercept term to comply with the criteria that cervical
156 cancer rates should be zero if the HPV prevalence is zero). In the regression model, we also
157 included age at HPV detection and location-specific time-lag (time between assessment of HR
158 HPV prevalence and cancer incidence in the same 10-year birth cohort; <10 or \geq 10 years) as
159 modifiers of the effect of HPV prevalence on cervical cancer incidence rates. Since cervical
160 cancer screening is an important confounding factor at a population level, we also conducted a
161 sensitivity analysis excluding data from locations with organized screening programmes with
162 reported coverage above 50%, i.e. Amsterdam, the Netherlands and Turin, Italy, hereafter
163 labelled as “locations with screening”.²¹ The other locations are considered as “locations without
164 screening” for the purpose of the present analysis.^{11,22}

165 **Cervical cancer incidence among HR HPV positive women**

166 In this analysis, we included a subset of 16 locations (appendix p 7, Table S1) for which cervical
167 cancer incidence data from CI5 Volumes VIII-XI covered relevant time intervals, to calculate
168 country-standardized and cohort-specific cervical cancer incidence rates in HR HPV positive
169 women (only Ho Chi Minh City, Vietnam, was excluded). We stratified our populations in the
170 age groups 20-24, 25-34, 35-44, and 45-54 year-old at HPV detection. For each location and year
171 since HPV measurement, we calculated the cohort-specific number of HR HPV positive women

172 and cervical cancers, and computed the cohort-specific incidence of cervical cancer in HR HPV
173 positive women (see appendix p 2, Figure S1 for details).

174 To estimate cohort-specific incidence of cervical cancer in women with prevalent HR
175 HPV infection, we fitted, for each age-group at HPV detection, a mixed effect linear regression
176 model with years since HPV detection, average age at sexual debut, their interaction, and
177 screening implementation status as covariates, location as grouping variable, and the risk of
178 cervical cancer (on a log scale) as an outcome. To be able to include at least three locations in
179 each analysis, we limited the time interval for cancer incidence estimates to 14 years. For the
180 same 14 locations without screening, average age at sexual debut (appendix p 8, Table S2) was
181 estimated from the IARC HPV Prevalence Surveys database,¹⁷ whereas for Amsterdam and
182 Turin it was obtained from national population-based surveys.^{23,24} To minimize the impact on
183 our findings of HPV prevalence estimates based on few HPV infections, we also performed a
184 sensitivity analysis restricted to 14 locations in which HPV prevalence was estimated on at least
185 ten infections in each age group (i.e. we excluded Barcelona, Spain, and Songkla, Thailand).
186 Based on mixed effect model-based estimates, we have drawn cervical cancer incidence
187 predictions for specific ages at sexual debut and, based on the fixed effect component of the
188 regression models, we predicted the incidence in each location. We used bootstrap for mixed
189 models to calculate 95% prediction intervals (PIs) of cervical cancer incidence.

190 Finally, to exemplify how the proposed model can be used to predict cervical cancer
191 incidence from estimates of age-specific HR HPV prevalence and average age at sexual debut,
192 we used data from IARC population-based HPV surveys not included in the previous analysis
193 (due to unavailability of cancer incidence data from CI5) to calculate the expected annual

194 cervical cancer burden (numbers and incidence) in the population of the corresponding country
195 ten years after the implementation of the surveys.

196 **Role of the funding source**

197 The funder of the study had no role in study design, data collection, data analysis, data
198 interpretation, or writing of the report. The corresponding author had full access to all the data in
199 the study and had final responsibility for the decision to submit for publication.

200 **Results**

201 Fig 1 shows, for 17 locations, cervical cancer incidence rates per 100 000 women plotted against
202 HR HPV prevalence, by age group, as well as the estimated effect of HR HPV prevalence on
203 cervical cancer incidence rates. Estimated cervical cancer incidence increased with HR HPV
204 prevalence in all age groups. The size of the effect of HPV prevalence on cancer incidence rates
205 increased with age and was also systematically higher in locations with a longer time-lag
206 between HPV and cervical cancer assessment in the same birth cohorts (Fig 1). The effect ranged
207 from 0.83 (0.75–0.9) to 2.3 (2.2–2.4) for women aged 25–34 years at HR HPV detection and
208 from 4.6 (4.3–5.0) to 7.4 (7.0–7.8) for women aged 55–64 years, for a time-lag of <10 and ≥10
209 years, respectively (Table 1). Effect estimates were not materially different in a sensitivity
210 analysis excluding locations with screening (appendix p 9, Table S3).

211 Results of the mixed effect regression model are shown in Table 2. Time-lag between HR
212 HPV prevalence and cancer incidence assessment significantly affected cervical cancer risk in
213 women below 35 years of age, and was also significantly modified by the average age at sexual
214 debut. Above age 35, however, cervical cancer risk was not affected by either variable. The
215 intraclass correlation coefficient, i.e. the proportion of the variance explained by setting location
216 as grouping variable, increased with age from 0.6 in 20 to 24 year-olds to more than 0.9 in 45 to
217 54 year-olds. Similar results were obtained analysing the dataset restricted to locations with at
218 least ten HPV infections in each age group (appendix pp 10-11, Table S4).

219

220

221 Fig 2 shows the annual incidence of cervical cancer (per 1000 HPV positive women) over
222 a period of 14 years following HPV detection, by age group at HPV detection. Cervical cancer
223 incidence is shown for each of the 16 locations (thin curves), as well as the model-based
224 predictions for locations with (thick solid) and without (thick dotted) screening. For 20 to 24
225 year-olds, cervical cancer incidence increases by approximately one order of magnitude over the
226 14-year period following HR HPV detection, e.g. 0.13 (0.09-to-0.2) to 2.3 (1.6-to-3.5) per 1000
227 HR HPV infected women in locations without screening (see appendix p 12, Table S5 for more
228 details). With increasing age, increases in cervical cancer risk with time since HR HPV detection
229 are less strong, so that among 45 to 54 year-olds, cervical cancer risk plateaus between 6.6 (4.3-
230 to-10.4) and between 5.7 (3.7-to-8.8) cancers per 1000 HR HPV infected women over the 14
231 years. Cervical cancer risk was higher in locations with than without screening, with this risk
232 difference increasing with age at HPV detection (Fig 2).

233 Fig 3 shows estimated cervical cancer risk in the 14-year period following HR HPV
234 detection, restricted to locations without screening, according to average sexual debut. Below 35
235 years-old, average age at sexual debut is an important modifier of cervical cancer risk in HPV-
236 positive women, with earlier sexual debut being associated with a higher initial risk. For
237 example, at age 20 to 24, the initial risk of cancer was 0.2 (0.1-to-0.3), 0.06 (0.03-to-0.1), and
238 0.02 (0.003-to-0.06) for average sexual debut at 17, 20, and 23 years, respectively. However,
239 these risks converge 14 years later: 2.3 (1.4-to-3.8), 2.2 (1.1-to-4.6), and 2.2 (0.5-to-10.7),
240 respectively. In contrast, in women with HR HPV detection at older ages, age at sexual debut
241 was not a strong modifier of cervical cancer risk. More details about the estimated risk of
242 cervical cancer in HPV positive women for locations with and without screening are provided in
243 appendix pp 13-14, Table S6. Also, panels in appendix p3, Fig S2, display the match between

244 predictions drawn using the fixed effect component of the regression models and cervical cancer
245 incidence among HPV positive women in each location.

246 Table 3 shows, for IARC population-based surveys without corresponding cancer
247 registries, and hence excluded from previous analyses, the predicted annual number and
248 incidence of cervical cancer (with 95% PIs) in the population of the corresponding country ten
249 years later. In all countries, the predicted annual incidence increased with age, with the lowest
250 predicted incidence in Pakistan, ranging from 1.2 (0.5-to-2.9) to 12.6 (5.0-to-30.8) per 100 000
251 women, among 30-34 and 55-64 year-old women, respectively, and the highest predicted
252 incidence in Guinea, ranging from 34 (13.5-to-87.9) to 262 (91.5-to-715.3) per 100 000 women.

253 **Discussion**

254 We have characterized and quantified the relationship between age-specific HPV prevalence and
255 cervical cancer incidence in the same female birth cohorts. We found a strong and positive effect
256 of HR HPV prevalence on cervical cancer incidence, which increased with age at HPV detection
257 and with time-lag between HR HPV prevalence and cancer incidence assessment. In a mixed
258 model approach, we went on to show that annual cervical cancer incidence among women with
259 prevalent HPV infection increases with age at HPV detection and, that in women below age 35,
260 cervical cancer risk changes by average age at first sex and increases in the 14 years following
261 HR HPV detection. In the absence of screening, depending upon the combination of age at
262 prevalent HR HPV detection and age at sexual debut, annual cervical cancer incidence ranged
263 from 0.02 (0.003-to-0.06) to 8.4 (3.3-to-22.0) per 1000 HR HPV positive women. The model
264 showed that annual cervical cancer incidence among HPV positive women was lower in
265 screened than unscreened populations. Thus, this model allows predictions of annual cancer
266 incidence from HPV prevalence data, in countries without cancer registration, an exercise that
267 we performed on a set of other IARC population-based HPV surveys.

268 Ecologic inference has been previously used by Maucort-Boulch *et al.*²⁵ and Sharma *et*
269 *al.*²⁶ to assess international correlation between HPV prevalence and cervical cancer incidence
270 measured in the same time period and same age groups in 13 and 40 different locations,
271 respectively (i.e. without accounting for the time-lag between HR HPV prevalence and cancer
272 incidence assessment to assess the birth-cohort-specific correlation). In both analyses, HPV
273 prevalence was a better predictor of cervical cancer at older ages, probably because prevalent
274 HPV infections in older women are more likely to be persistent and at a higher risk of causing a
275 cervical cancer.²⁷ This hypothesis is reinforced by our finding that the association between HPV

276 prevalence and cervical cancer incidence increased not only with age at HPV detection but also
277 with the time-lag between HR HPV prevalence and cancer incidence measurement.

278 Our observations a) that cervical cancer incidence among women below 35 years with
279 prevalent HR HPV infection is modulated by age at first sex, as a proxy of early exposure to
280 HPV infection, and b) that cervical cancer incidence increases until approximately 45 years of
281 age and subsequently remains constant, are consistent with data from unscreened populations²⁸
282 and with the hypothesis that risk inflexion in middle age corresponds to a drop in circulating sex
283 hormone levels during the perimenopausal period.²⁹ Plummer et al. also observed an increase of
284 cervical cancer risk associated with time since first sexual intercourse, while analysing a very
285 large epidemiological data set on cervical cancer.³⁰ Similarly, their risk estimates flattened
286 approximately at age 45 years and remained constant at older ages.

287 We have adapted our study design to account for some typical limitations of ecological studies.
288 First, to account for the latency between exposure and outcome (which is missed by concurrent
289 measurement of HR HPV prevalence and cervical cancer incidence), we have assessed the two
290 measurements in the same birth cohorts and have incorporated the time-lag between the two
291 measurements. Second, we matched HPV and cervical cancer data from the same (or similar)
292 location, to geographically match, as far as possible, exposure and outcome measurements.
293 Third, we accounted for age at first sex and cervical cancer screening as a possible confounder of
294 the ecologic relationship in the same locations between HPV prevalence and cervical cancer
295 incidence. The effect of screening in Amsterdam and Turin on the risk of cervical cancer among
296 HPV positive women (that was detectable with a fixed effect model - data not shown), was
297 accounted for in the mixed effect model by the between-location variance and intraclass
298 correlation coefficient. Analogously, the effect of other location-related determinants of cervical

299 cancer risk given prevalent HR HPV detection, such as HIV status, reproductive behaviour
300 factors, hormonal contraceptive use, and smoking, for which we were unable to explicitly
301 account for, may also have been captured by the between-location variance. Consequently, our
302 predictions of the annual incidence of cervical cancer in countries not represented in CI5 are
303 based on average age at sexual debut, time elapsed since HPV assessment, as well as on the age-
304 specific HR HPV prevalence assessed in each survey. The accuracy of the reported predictions
305 relies on the assumption that the age-specific HR HPV prevalence assessed in the survey is
306 representative of the prevalence in the whole country.

307 Our estimates of the risk of cervical cancer among HR HPV positive women are based
308 upon the systematic use of the GP5+/6+ test, which is validated for clinical purposes. Hence our
309 findings should be applicable to other population-based datasets obtained using HPV tests with a
310 similar sensitivity, but may be less applicable to prevalence data generated with more sensitive
311 methods.

312 In conclusion, using worldwide, high quality, standardized data on age-specific HPV
313 prevalence and cervical cancer incidence, we have estimated age-specific cervical cancer
314 incidence over time elapsed since prevalent HPV detection as a function of average age at first
315 sex in the female population. This finding can be particularly useful to design and plan cancer
316 control programmes in settings without cancer registries, as it allows, as exemplified above, a
317 predictive assessment of the expected burden of cervical cancer from data collected through
318 population-based cross-sectional HPV prevalence surveys, which are relatively easy to
319 implement.

320

321

322 **Contributors**

323 RSF and IB conceived and designed the study. RSF, DG, and IB collected and analysed the data.
324 RSF, GC, and IB drafted the manuscript. All authors contributed to the interpretation of data and
325 approved the final manuscript.

326

327 **Funding**

328 This work was supported by the Bill & Melinda Gates Foundation [OPP 1188709]; and the
329 Canadian Institutes of Health Research [334069].

330

331 **Declaration of interests**

332 We declare no competing interests.

333

334 **Acknowledgments**

335 The authors would like to thank Professor Delphine Maucort-Boulch for her technical advice,
336 and Doctor Silvia Franceschi, Professor Julian Peto and Doctor Guglielmo Ronco for their
337 helpful comments. Where authors are identified as personnel of the International Agency for
338 Research on Cancer and WHO, the authors alone are responsible for the views expressed in this
339 article and they do not necessarily represent the decisions, policy or views of the International
340 Agency for Research on Cancer and WHO.

341

342 **References**

- 343 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
344 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in
345 185 countries. *CA Cancer J Clin* 2018; **68**(6): 394-424.
- 346 2. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer
347 attributable to HPV by site, country and HPV type. *Int J Cancer* 2017; **141**(4): 664-70.
- 348 3. IARC. Biological agents. *IARC Monogr Eval Carcinog Risks Hum*, 2012.
349 <https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100B.pdf> (accessed Jan 20, 2020).
- 350 4. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115,789 HPV-
351 positive women: A meta-analysis from cervical infection to cancer. *Int J Cancer* 2012; **131**(10):
352 2349-59.
- 353 5. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human
354 papillomaviruses to prevent cervical cancer and its precursors. *The Cochrane database of*
355 *systematic reviews* 2018; **5**: CD009069.
- 356 6. Markowitz LE, Gee J, Chesson H, Stokley S. Ten Years of Human Papillomavirus
357 Vaccination in the United States. *Academic pediatrics* 2018; **18**(2s): S3-s10.
- 358 7. Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after
359 immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population
360 study. *Bmj* 2019; **365**: 11161.
- 361 8. Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPV-
362 associated cancers. *Int J Cancer* 2018; **142**(10): 2186-7.
- 363 9. World Health Organization. Human papillomavirus vaccines: WHO position paper, May
364 2017. *Wkly Epidemiol Rec* 2017; **92**(19): 241-68.

- 365 10. Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus
366 vaccination coverage by region and income level: a pooled analysis. *The Lancet Global Health*
367 2016; **4**(7): e453-63.
- 368 11. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57
369 countries: low average levels and large inequalities. *PLoS Med* 2008; **5**(6): e132.
- 370 12. World Health Organization. WHO leads the way towards the elimination of cervical
371 cancer as a public health concern. [https://www.who.int/reproductivehealth/cervical-cancer-](https://www.who.int/reproductivehealth/cervical-cancer-public-health-concern/en/)
372 [public-health-concern/en/](https://www.who.int/reproductivehealth/cervical-cancer-public-health-concern/en/) (accessed Jan 20, 2020).
- 373 13. Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R and Ferlay J, editors
374 (2017). *Cancer Incidence in Five Continents, Vol. XI* (electronic version). Lyon: International
375 Agency for Research on Cancer. Available from: <http://ci5.iarc.fr> (accessed Jan 20, 2020).
- 376 14. Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer
377 elimination in Australia: a modelling study. *Lancet Public Health* 2019; **4**(1): e19-e27.
- 378 15. Vaccarella S, Franceschi S, Zaridze D, et al. Preventable fractions of cervical cancer via
379 effective screening in six Baltic, central, and eastern European countries 2017-40: a population-
380 based study. *Lancet Oncol* 2016; **17**(10): 1445-52.
- 381 16. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk
382 of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort
383 study. *Lancet Oncol* 2008; **9**(5): 425-34.
- 384 17. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and
385 cervical cancer. *Lancet* 2013; **382**(9895): 889-99.

- 386 18. Parkin DM, Whelan SL, Ferlay J, Thomas DB, Teppo L. Cancer Incidence in Five
387 Continents, Volume VIII. IARC Scientific Publications No. 155. Lyon: Lyon, France :
388 International Agency for Research on Cancer, 2002; 2002.
- 389 19. Curado MP, Edwards B, Shin HR, et al. Cancer Incidence in Five Continents, Vol. IX.
390 IARC Scientific Publication No. 160. Lyon: IARC; 2007.
- 391 20. Forman D, Bray F, Brewster DH, et al. Cancer Incidence in Five Continents, Vol. X.
392 IARC Scientific Publication No. 164. Lyon, France: International Agency for Research on
393 Cancer; 2014.
- 394 21. Basu P, Ponti A, Anttila A, et al. Status of implementation and organization of cancer
395 screening in The European Union Member States-Summary results from the second European
396 screening report. *Int J Cancer* 2018; **142**(1): 44-56.
- 397 22. Pan American Health Organization. Cervical Cancer Prevention and Control Programs: A
398 rapid assessment in 12 countries of Latin America. Washington, D.C.: PAHO; 2010.
- 399 23. de Graaf H MS, Poelman J, Vanwesenbeeck I. Seks onder je 25e Definitieve
400 Resultaten2005.
401 <https://www.edudivers.nl/doc/onderzoek/rapport%20Seks%20onder%20je%2025e.pdf> (accessed
402 Jan 20, 2020).
- 403 24. Signorelli C, Pasquarella C, Limina RM, et al. Third Italian national survey on
404 knowledge, attitudes, and sexual behaviour in relation to HIV/AIDS risk and the role of health
405 education campaigns. *Eur J Publ Health* 2006; **16**: 498-504.
- 406 25. Maucort-Boulch D, Franceschi S, Plummer M. International correlation between human
407 papillomavirus prevalence and cervical cancer incidence. *Cancer Epidemiol Biomarkers Prev*
408 2008; **17**(3): 717-20.

- 409 26. Sharma M, Bruni L, Diaz M, et al. Using HPV prevalence to predict cervical cancer
410 incidence. *Int J Cancer* 2013; **132**(8): 1895-900.
- 411 27. Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus
412 infection. *Nature Reviews Disease Primers* 2016; **2**: 16086.
- 413 28. Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of
414 invasive cervical cancer before cytological screening. *Int J Cancer* 1997; **71**(2): 159-65.
- 415 29. Pike MC, Pearce CL, Wu AH. Prevention of cancers of the breast, endometrium and
416 ovary. *Oncogene* 2004; **23**(38): 6379-91.
- 417 30. Plummer M, Peto J, Franceschi S. Time since first sexual intercourse and the risk of
418 cervical cancer. *Int J Cancer* 2012; **130**(11): 2638-44.
- 419

420 **Table 1.** Estimated effect of HR HPV prevalence on cervical cancer incidence rates by age at
 421 HPV detection and time-lag between HPV prevalence and cancer incidence measurement.

Time-lag (years)*	Age group at HPV detection (years)			
	25–34	35–44	45–54	55–64
<10	0.83 (0.75–0.9)	2.4 (2.3–2.6)	3.5 (3.3–3.7)	4.6 (4.3–5)
≥10	2.3 (2.2–2.4)	5.8 (5.6–6)	6 (5.7–6.3)	7.4 (7–7.8)

422

423 *Years elapsed between HR HPV detection and cervical cancer incidence assessment in the same
 424 birth cohorts. HR HPV = high-risk human papillomavirus.

425

426 **Table 2.** Results of the mixed effect linear regression models, by age group at HPV detection.

Age group at HPV detection (years)	Variable	Coefficient	95% CI	P-Value
20–24	Intercept	-0.94	(-5.80–3.91)	0.723
	Time-lag (years)*	-0.36	(-0.63– -0.10)	0.008
	Age at sexual debut (years)	-0.44	(-0.71– -0.18)	0.008
	Screening [†]	-0.58	(-1.50–0.33)	0.259
	Effect modification of age at sexual debut on time-lag	0.0313	(0.017–0.047)	0.0001
	Within-location variance	0.18
	Between-location variance	0.35
	Intraclass correlation coefficient	0.66
	Conditional R ²	0.86
25–34	Intercept	-4.39	(-8.82–0.04)	0.085
	Time-lag (years)*	-0.11	(-0.22– -0.01)	0.042
	Age at sexual debut (years)	-0.13	(-0.35–0.09)	0.288
	Screening [†]	-0.7	(-1.96–0.57)	0.321
	Effect modification of age at sexual debut on time-lag	0.0097	(0.004–0.015)	0.001
	Within-location variance	0.07
	Between-location variance	0.68
	Intraclass correlation coefficient	0.91
	Conditional R ²	0.92
35–44	Intercept	-4.32	(-8.96–0.31)	0.103
	Time-lag (years)*	0	(-0.09–0.09)	0.985
	Age at sexual debut (years)	-0.06	(-0.29–0.17)	0.626
	Screening [†]	-0.83	(-2.15–0.49)	0.257
	Effect modification of age at sexual debut on time-lag	0.0004	(-0.004–0.005)	0.872
	Within-location variance	0.05
	Between-location variance	0.68
	Intraclass correlation coefficient	0.94
	Conditional R ²	0.94
45–54	Intercept	-3.3	(-8.07–1.46)	0.215
	Time-lag (years)*	-0.06	(-0.15–0.03)	0.179
	Age at sexual debut (years)	-0.08	(-0.31–0.15)	0.508
	Screening [†]	-0.76	(-2.07–0.54)	0.294

Effect modification of age at sexual debut on time-lag	0.0025	(-0.002–0.007)	0.282
Within-location variance	0.04
Between-location variance	0.65
Intraclass correlation coefficient	0.94
Conditional R ²	0.95

427

428 CI=confidence interval. HPV=human papillomavirus. *Years elapsed between HR HPV detection and cervical cancer

429 incidence assessment. †Effect of organized screening with coverage >50%.

430 **Table 3.** Expected annual number and incidence (per 100 000 women) of cervical cancer, ten years after the implementation of the
 431 surveys.

Characteristics of the HPV survey			Population in the country ^a				Expected cervical cancer (95% CI)			
Country	Location	Year	Age group	HR HPV Prevalence (%)	Average age at sexual debut	N women	Expected N of HR HPV positive women	Age group	Number (95% PI)	Incidence per 100 000 women (95% PI)
Bhutan	Thimphu, Lungtenphu	2011–12	20–24	22.3%	19	32 076	7137	30–34	6 (2–16)	19.7 (7.7–50.3)
			25–34	18.9%	20	48 529	9170	35–44	18 (9–35)	37.7 (19.4–72.7)
			35–44	14.3%	20	33 459	4769	45–54	21 (11–40)	62.2 (33.3–119.3)
			45–54	11.2%	19	21 116	2373	55–64	15 (8–28)	70.5 (38.6–134.1)
Georgia	Tbilisi	2007	20–24	12.3%	19	175 471	21 509	30–34	20 (7–52)	11.2 (4.2–29.6)
			25–34	12.2%	20	321 833	39 408	35–44	82 (41–152)	25.4 (12.8–47.3)
			35–44	4.8%	22	335 425	15 973	45–54	62 (31–125)	18.6 (9.2–37.4)
			45–54	6.2%	23	317 977	19 669	55–64	101 (46–238)	31.9 (14.6–74.9)
Guinea	Conakry	2006	20–24	29.9%	17	422 643	126 398	30–34	143 (57–372)	34.0 (13.5–87.9)
			25–34	28.7%	17	633 390	181 806	35–44	394 (159–938)	62.2 (25.1–148.0)
			35–44	25.4%	17	447 604	113 864	45–54	564 (222–1409)	126.1 (49.6–314.7)
			45–54	36.0%	17	340 426	122 455	55–64	892 (311–2435)	262.0 (91.5–715.3)
Mongolia	Ulanbataar	2005	20–24	40.2%	19	129 903	52 260	30–34	43 (16–116)	33.3 (12.3–89.4)
			25–34	24.2%	21	223 403	54 132	35–44	107 (53–207)	47.7 (23.6–92.7)
			35–44	17.5%	21	181 801	31 798	45–54	128 (68–243)	70.4 (37.5–133.5)
			45–54	17.3%	20	106 259	18 354	55–64	109 (63–189)	102.6 (58.9–178.2)
Nepal	Bharatpur	2006–7	20–24	5.7%	17	1 158 460	65 728	30–34	79 (31–195)	6.8 (2.6–16.9)
			25–34	5.6%	18	1 920 287	107 384	35–44	231 (99–505)	12.0 (5.1–26.3)
			35–44	7.9%	18	1 335 815	106 094	45–54	501 (223–1198)	37.5 (16.7–89.7)
			45–54	5.5%	17	944 642	51 761	55–64	369 (132–1008)	39.0 (14.0–106.7)
Nigeria	Ibadan	1999	20–24	19.0%	17	5 557 934	1 058 654	30–34	1165 (482–3197)	21.0 (8.7–57.5)
			25–34	14.3%	19	8 182 426	1 168 918	35–44	2548 (1254–5021)	31.1 (15.3–61.4)
			35–44	18.7%	19	5 638 379	1 051 936	45–54	4740 (2551–9091)	84.1 (45.2–161.2)

Characteristics of the HPV survey			Population in the country*				Expected cervical cancer (95% CI)			
Country	Location	Year	Age group	HR HPV Prevalence (%)	Average age at sexual debut	N women	Expected N of HR HPV positive women	Age group	Number (95% PI)	Incidence per 100 000 women (95% PI)
Pakistan	South Karachi	2006	45–54	16.8%	20	3 978 221	669 803	55–64	4178 (2298–7576)	105.0 (57.8–190.4)
			20–24	1.2%	18	7 090 156	85 424	30–34	84 (36–208)	1.2 (0.5–2.9)
			25–34	2.1%	20	10 730 124	224 480	35–44	454 (233–925)	4.2 (2.2–8.6)
			35–44	0.8%	19	7 984 107	64 649	45–54	289 (148–577)	3.6 (1.8–7.2)
			45–54	1.7%	17	5 244 948	91 482	55–64	662 (260–1614)	12.6 (5.0–30.8)
Rwanda	Kigali	2013–4	20–24	28.4%	18	515 301	146 404	30–34	150 (62–360)	29.0 (12.1–69.9)
			25–34	21.2%	20	1 017 610	215 678	35–44	450 (234–882)	44.3 (23.0–86.6)
			35–44	14.3%	21	589 561	84 223	45–54	354 (198–671)	60.0 (33.6–113.8)
			45–54	13.0%	21	376 934	49 061	55–64	287 (160–506)	76.1 (42.6–134.1)
Vanuatu	Port Vila	2009–10	20–24	31.6%	18	11 876	3750	30–34	4 (2–9)	32.1 (12.8–75.1)
			25–34	21.1%	19	17 714	3746	35–44	8 (4–16)	44.6 (20.5–90.9)
			35–44	18.0%	19	12 896	2327	45–54	11 (5–23)	83.6 (40.2–178.3)
			45–54	9.3%	19	9 452	877	55–64	6 (3–11)	61.1 (29.8–117.4)
Viet Nam	Ho Chi Minh City	1997	20–24	9.4%	20	3 549 293	334 051	30–34	263 (94–718)	7.4 (2.6–20.2)
			25–34	5.8%	23	6 123 615	356 024	35–44	671 (258–1714)	11.0 (4.2–28.0)
			35–44	7.0%	24	4 465 621	313 800	45–54	1122 (395–3098)	25.1 (8.9–69.4)
			45–54	4.5%	23	2 299 986	103 870	55–64	515 (210–1275)	22.4 (9.2–55.4)

432

433

CI=confidence interval. HR HPV=high-risk human papillomavirus. PI=prediction interval. *Source: World Population Prospects 2019, United Nations Population Division,

434

<https://population.un.org/wpp/>.

435

436

437 **Figure Legends**

438 **Fig 1.** Birth cohort-specific HR HPV prevalence and cervical cancer incidence rates, by age-
439 group at HPV detection, time-lag between HR HPV prevalence measurement and cervical cancer
440 detection, and location. Colored lines represent effect estimates (with 95% confidence intervals)
441 obtained fitting a Poisson regression model. HR HPV=high-risk human papillomavirus.

442 **Fig 2.** Cervical cancer incidence rates in HR HPV positive women, by years since HR HPV
443 detection, age-group at HPV detection, screening implementation status and location. Model-
444 based projections were drawn assuming the following average age at sexual debut in locations
445 without and with screening, respectively, 18.3 and 16.9 years (age group 20 to 24); 19.7 and
446 17.6 years (age group 25–34); 20 and 17.5 (age group 35–44); and 20.3 and 17.7 (age group 45–
447 54). HR HPV=high-risk human papillomavirus.

448 **Fig 3.** Cervical cancer incidence rates in HR HPV positive women in locations without
449 screening, by years since HR HPV detection, age-group at HR HPV detection, average age at
450 sexual debut, and location. HR HPV=high-risk human papillomavirus.

451

452

453

454

455

Figure 1




Figure 2 20–24 year-old 25–34 year-old 35–44 year-old 45–54 year-old




Figure 3 20–24 year-old 25–34 year-old 35–44 year-old 45–54 year-old

